// App-Quantinova.ai

: Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial

Researchers

Presenter

  • Steven R. Feldman

Principal Investigators

  • Alice B. Gottlieb

  • Jennifer Soung

  • Matthias Augustin

  • Paolo Gisondi

  • Luke Peterson

  • Veerle Vanvoorden

  • Valerie Ciaravino

  • Natalie Nunez Gomez

  • Richard B. Warren

Medical Centers

  • Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, NC

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Southern California Dermatology Inc., Santa Ana, CA, USA

  • Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg, Hamburg, Germany

  • University of Verona, Verona, Italy

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Colombes, France

  • The Dermatology Centre, Salford Royal NHS Foundations Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, University of Manchester, Manchester, UK

Locations

  • United States

  • France

  • United Kingdom

  • Italy

  • Belgium

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved